zerbor
4 June 2018Big Pharma

French court knocks out Gilead Truvada SPC

The Paris Court of First Instance has nullified a supplementary protection certificate (SPC) covering Gilead’s HIV/AIDS treatment Truvada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,

More on this story

Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,

More on this story

Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,